These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22310610)

  • 1. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
    Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
    Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
    Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up.
    Billing H; Rieger S; Süsal C; Waldherr R; Opelz G; Wühl E; Tönshoff B
    Transpl Int; 2012 Nov; 25(11):1165-73. PubMed ID: 22897111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
    Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
    Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
    Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
    Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
    Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
    Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
    Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
    Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients.
    An GH; Yun J; Hong YA; Khvan M; Chung BH; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
    J Immunol Res; 2014; 2014():828732. PubMed ID: 24741626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection.
    Ban TH; Yu JH; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
    Ann Transplant; 2017 Aug; 22():468-474. PubMed ID: 28775248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
    Kimball PM; King A
    Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
    Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
    Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
    Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early diagnosis and successful treatment of acute antibody-mediated rejection of a renal transplant.
    Yang YW; Lin WC; Wu MS; Lee PH; Tsai MK
    Exp Clin Transplant; 2008 Sep; 6(3):211-4. PubMed ID: 18954299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.